Prophylactic oophorectomy: A historical perspective

Journal of Epidemiology and Community Health

Volumn 61, Issue 3, 2007, Pages 182-184

  Moscucci, Ornella ^a   Clarke, Aileen ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Public Health Resource Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER; COST-BENEFIT ANALYSIS; HEALTH RISK; NINETEENTH CENTURY; REPRODUCTIVE HEALTH; RISK FACTOR; WOMENS HEALTH;

ABORTION; ADDICTION; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTRACEPTION; COST BENEFIT ANALYSIS; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; OVARIECTOMY; OVARY CANCER; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW; UTERINE CERVIX CANCER;

ATTITUDE OF HEALTH PERSONNEL; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY;

EURASIA; EUROPE; UNITED KINGDOM; WESTERN EUROPE;

EID: 34147198069     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2006.046474     Document Type: Review

References (35)

1. Fignon A, Marret H, Lansac J. Bilateral ovarian removal during hysterectomy: what is done and what should be done. Eur J Obstet Gynecol Reprod Biol 1998;76:201-5.
2. Vuorma S, Teperi J, Hurskainen R, et al. Hysterectomy trends in Finland 1987-1995 - a register based analysis. Acta Obstet Gynaecol Scand 1998;77:770-6.
3. Progetto Menopausa Italia Study Group. Determinants of hysterectomy and oophorectomy in women attending menopause clinics in Italy. Maturitas 2000;36:19-25.
4. Lewis CE, Groff JY, Herman G, et al. Overview of women's decision making regarding elective hysterectomy, oophorectomy and hormone replacement therapy. J Women's Health Gender Based Medi 2000;9(Suppl 2):S5-14.
5. Kauff ND, Satagopan JM, Scheuer L, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
6. Clarke A, Chang YM, McPherson K. Removing organs "just in case"-is prophylactic removal of the ovaries a good thing? J Epidemiol Community Health 2006;60:186-7.
7. Moscucci O. The science of woman: gynaecology and gender in England, 1800-1929. Cambridge: Cambridge University Press, 1990.
8. Borell ME. Origins of the hormone concept: internal secretions and physiological research, 1869-1905 [PhD thesis], Yale: Yale University, 1976.
9. Sengoopta C. The most secret quintessence of life: sex, glands, and hormones, 1850-1950. Chicago: University of Chicago Press, 2006.
10. McIlroy AL. The physiological influence of ovarian secretion. Proc R Soc Med 1912;5(Pt II):342-70.
11. Biedl A. The internal secretory organs: their physiology and pathology. London: John Bale, Sons & Danielsson, 1913.
12. Bell WB. The relations of the internal secretions to the female characteristcs and functions in health and disease. Proc R Soc Med 1914;7(Pt II):47-100.
13. Hendry J. The results of conservative treatment of the ovaries. J Obstet Gynaecol Br Empire 1936;43:609-18.
14. Bonney V. The fruits of conservatism. J Obstet Gynaecol Br Empire 1937;44:1-12.
15. Moscucci O. Gender and cancer in Britain, 1860-1910: the emergence of a public health concern. Am J Public Health 2005;95:1312-21.
16. Crossen HS. The menace of "silent" ovarian carcinoma. JAMA 1942;119:1485-9.
17. Solomons E. A survey of the results of repair and amputation of the cervix. J Obstet Gynaecol Br Empire 1940;47:461-73.
18. Bonney V. A textbook of gynaecological surgery. London: Cassell, 1952.
19. Macleod D, Howkins J. Bonney's gynaecological surgery, 7th edn. London: Cassell, 1964.
20. Bishop PMF, Boycott M, Zuckermann S. Estrogenic properties of "stilbestrol" (diethylstilbestrol): clinical and experimental investigations. Lancet 1939;2:5-11.
21. Shorr E, Robinson FH, Papanicolaou GN. A clinical study of the synthetic estrogen slylbestrol. JAMA 1939;113:2312-18.
22. Buxton CL, Engle ET. Effects of the therapeutic use of diethylstilboestrol. JAMA 1939;113:2318-20.
23. Varangot J. Clinical use of stilboestrol [letter]. Lancet 1939;1:296.
24. Anon. Risks of oestrogens [editorial]. Lancet 1940;1:461-2,.
25. Cook JW, Dodds CW, Hewett CL. A synthetic oestrus-exciting compound. Nature 1933;131:56-7.
26. Hunt E. Oestrin and cancer [letter]. Lancet 1936;2:1431.
27. Bishop PMF, Dodds CW. Oestrin and cancer [letter]. Lancet 1936;2:1489.
28. Parkes AS, Bishop PMF, Dodds CW. Oestrin and cancer [letter]. Lancet 1936;2:1365-66.
29. Cramer W, Gye WE. Oestrin and cancer [letter]. Lancet 1936;2:1365.
30. Barr DP. The George E. Brown Memorial Lecture: some chemical factors in the pathogenesis of atherosclerosis, Circulation 1953;8:641-54.
31. Oliver MF, Boyd GS. Effects of bilateral ovariectomy on coronary-artery disease and serum-lipid levels. Lancet 1959;2:690-4.
32. Anon. Hysterectomy: with or without oophorectomy? [editorial]. Lancet 1960;2:918.
33. Jeffcoate TNA. Principles of gynaecology. London: Butterworth, 1957.
34. Nixon W. Conservation of the ovaries [letter]. Lancet 1960;2:981.
35. Anderson K, Jacobson JS, Heitjan DF, et al, Cost-effectiveness of preventive strategies for women with BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:140.